Trial Profile
An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Sanofi
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 16 Jun 2018 Results of pooled data from two trials (NCT02404558 and NCT02097524), were presented at the 19th Annual Congress of the European League Against Rheumatism.
- 25 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.